MindMed Begins Study On LSD Neutralizer Technology
MindMed (NEO: MMED) this morning announced that it has begun a study on what it refers to as “LSD neutralizer technology.” The tech is intended to stop the effects of an LSD trip while a patient is undergoing a therapy session.
The study is being conducted with the University Hospital Basel’s Liechti Lab via a phase one trial, which will evaluate the effect of ketanserin on the response to LSD after LSD administration. The project is associated with the firms LSD therapy studies referred to as Project Lucy, with the company looking to improve the therapy session with additional features to create a better patient experience.
Expected to be completed by year end, the company is effectively looking to evaluate the compound for use as an “emergency-off” switch for psychedelic assisted therapies. The tech, if successful, is ideal for when a “bad trip” occurs for the patient, or the session is not going as intended.
The study will work under the premise that the administration of 40mg of ketanserin one hour after taking LSD will significantly shorten and reduce the effects of LSD, when compared to LSD alone and a placebo. The compound is currently marketed as an antihypertensive agent.
Mindmed last traded at $5.31 on the NEO.
Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
